Biogen expands biosimilars portfolio with Samsung Bioepis deal

Biogen is expanding its biosimilars portfolio and gaining access to additional markets through a new transaction with South Korea’s Samsung Bioepis.

The deal will see Biogen secure the exclusive rights to commercialise to new ophthalmology biosimilars – SB11 referencing Lucentis and SB15 referencing Eylea – in major markets worldwide, including the US, Canada, Europe, Japan and Australia.

In addition, Biogen will acquire exclusive commercialisation rights for its anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), in China.

Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.

The company said it expects the update of Benepali, Flixabi and Imraldi to generate around €1.8 billion in healthcare cost savings in 2019.

Biogen will make a $100 million upfront payment to Samsung Bioepis and will pay up to $210 million in additional development-, regulatory and sales-based milestones.

Biogen will also obtain an option to extend the term of its current European commercial agreement for its three anti-TNF biosimilars by an additional five years, subject to payment of an option exercise fee of $60 million.

Upon closing, Biogen expects to record a charge to research and development expense of approximately $65 million related to the $100 million upfront payment.

The deal is expected to close this quarter.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news